Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zanubrutinib and Rituximab in Untreated Indolent B-cell Lymphomas
NCT06350318Phase 2Recruiting
- Sponsor
- Moffitt Cancer Center
- Start
- Apr 2024
- Primary completion
- Mar 2029
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 1
01
Overview
Phase 2, open-label trial of zanubrutinib in marginal zone lymphoma (MZL) and follicular lymphoma (FL) (2 cohorts), sponsored by Moffitt Cancer Center. Primary endpoint: Overall Response Rate at 6 months. Started Apr 2024; status: recruiting.
02
Drugs
zanubrutinib
03
Conditions
marginal zone lymphoma (MZL)follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT06350318.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06350318.